Adaptive Biotechnologies (ADPT) Profit After Tax (2018 - 2026)

Adaptive Biotechnologies has disclosed Profit After Tax across 9 years of filings, most recently posting -$39.9 million for Q2 2026.

• In Q2 2026, Profit After Tax fell 55.93% year-over-year to -$39.9 million; the TTM figure through Jun 2026 stood at -$64.0 million (up 47.22% YoY), while the FY2025 annual figure was -$59.5 million, up 62.72% from the prior year.
• Profit After Tax came in at -$39.9 million for Q2 2026 at Adaptive Biotechnologies, down from -$20.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $9.5 million in Q3 2025 to a low of -$69.5 million in Q4 2023.
• Average Profit After Tax over 5 years is -$39.2 million, with a median of -$42.7 million recorded in 2022.
• Year-over-year, Profit After Tax tumbled 72.94% in 2023 and jumped 129.74% in 2025.
• Over 5 years, Profit After Tax stood at -$40.2 million in 2022, then plunged by 72.94% to -$69.5 million in 2023, then soared by 51.46% to -$33.7 million in 2024, then surged by 59.73% to -$13.6 million in 2025, then tumbled by 194.14% to -$39.9 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$39.9 million in Q2 2026, -$20.0 million in Q1 2026, and -$13.6 million in Q4 2025.